Medication info
Englina Tablet 10/5 mg (Empagliflozin, Linagliptin)

Englina Tablet 10/5 mg (Empagliflozin, Linagliptin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›5mg / 1 tabletEmpagliflozin Amorphous›10mg / 1 tablet
Manufacturer / importer
Daehwa Pharmaceutical Co., Ltd.
Appearance
Yellow film-coated tablets that are convex on both sides and round in shape
Packaging
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle, PTP - 30 tablets/PTP [10 tablets/PTP × 3]
Approval status
Active

MFDS item code 202502188 · Approved 2025.08.22 · Insurance code 645606010

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended starting dose of this drug is empagliflozin 10 mg/linagliptin 5 mg once daily. If additional glycemic control is needed and empagliflozin 10 mg/linagliptin 5 mg is tolerated, the dose of this drug may be increased to 25/5 mg once daily. Patients switching to this drug from combination therapy with empagliflozin and linagliptin should receive their previous doses. This drug may be taken with or without food. Swallow the tablet whole. If a dose of this drug is missed, take it as soon as remembered. However, if the next dose is due within 12 hours, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose in one day. Patients with renal impairment This drug is not recommended to improve glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2. No dosage adjustment is necessary in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or greater. Patients with hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. Since this drug has not been studied in patients with severe hepatic impairment, its use is not recommended. Elderly patients No dosage adjustment is necessary based on age. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Daehwa Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with diet and exercise to help patients with type 2 diabetes manage their blood sugar levels. It is particularly prescribed for individuals suitable for combined administration of Empagliflozin and Linagliptin to improve blood sugar control. This helps effectively manage diabetes symptoms.

How to take

Adult dose

The recommended starting dose of this drug is empagliflozin 10 mg/linagliptin 5 mg once daily. If additional glycemic control is needed and empagliflozin 10 mg/linagliptin 5 mg is tolerated, the dose of this drug may be increased to 25/5 mg once daily. Patients switching to this drug from combination therapy with empagliflozin and linagliptin should receive their previous doses. This drug may be taken with or without food. Swallow the tablet whole. If a dose of this drug is missed, take it as soon as remembered. However, if the next dose is due within 12 hours, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose in one day. Patients with renal impairment This drug is not recommended to improve glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2. No dosage adjustment is necessary in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or greater. Patients with hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. Since this drug has not been studied in patients with severe hepatic impairment, its use is not recommended. Elderly patients No dosage adjustment is necessary based on age. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication consists of two active ingredients: Empagliflozin and Linagliptin, primarily used for blood sugar control in patients with type 2 diabetes. This medication should not be administered to patients with allergies to Empagliflozin or Linagliptin, patients with type 1 diabetes, diabetic ketoacidosis, or patients undergoing dialysis. Patients with impaired kidney function should periodically check the efficacy and safety of this medication, especially before and after related medications and kidney function testing. It should be used with caution in patients with mild to moderate heart failure and is not recommended for patients with severe heart failure. Acute pancreatitis may occur while taking this medication; if severe abdominal pain persists, discontinue use immediately and consult a physician. Additionally, if blistering symptoms resembling bullous pemphigoid occur, discontinue this medication and consult a specialist. Urinary tract infections and genital fungal infections may occur frequently, necessitating prompt treatment for any symptoms of infection. There is a risk of hypoglycemia, particularly when taken together with insulin or sulfonylureas; therefore, blood sugar changes should be closely monitored. Symptoms of hypotension or dehydration may occur due to decreased fluid volume, particularly in the elderly or patients on antihypertensive medications, requiring careful monitoring of blood pressure and fluid status. This medication may cause a serious metabolic disturbance known as ketoacidosis; if symptoms such as vomiting, abdominal pain, or breathing difficulties occur, seek medical attention immediately. A rare but serious infection known as perineal necrotizing fasciitis has been reported; if pain or swelling in the perineum occurs, immediate medical attention is required. It is advisable to avoid this medication during pregnancy, and nursing mothers are recommended to discontinue breastfeeding. The safety and efficacy of this medication have not been established in children under 18 years; therefore, it is best not to use in this population. In case of overdose, seek appropriate medical treatment immediately, and this medication should be kept out of reach of children. While taking this medication, caution should be exercised while driving or operating machinery due to the risk of hypoglycemia; immediate action should be taken if symptoms occur.

Side effects

urinary tract infection, vulvar neuromuscular disease, vulvitis, balanitic, other genital infections, hypersensitivity, angioedema, urticaria, hypoglycemia, thirst, ketoacidosis, cough, constipation, pancreatitis, oral ulcer formation, itching, rash, vesicular pemphigoid, rhabdomyolysis, fluid volume depletion, increased urination, difficulty urinating, interstitial nephritis, increased amylase, increased lipase, increased hematocrit, increased serum lipids, upper abdominal pain, enterocolitis, bowel obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuritis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorder, Alzheimer's dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, rhabdomyolysis, fluid volume depletion, acute kidney injury, end-stage kidney disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, cerebral infarction, headache, drowsiness, chest discomfort, weakness, nosebleed, oropharyngeal pain, dysphonia, allergic rhinitis, exertional dyspnea, wet cough, runny nose, pulmonary mass, joint pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased triglycerides in blood, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased potassium in blood, increased creatinine in blood, increased creatine phosphokinase in blood, increased ALT, increased AST, male pattern baldness, hyperhidrosis, hair loss, dermatitis, anxiety, mood disorders, insomnia, depression, contusion, bone contusion, concussion, meniscus injury, foot fracture, hand fracture, pneumoconiosis, laceration, congestive heart failure, angina pectoris, acute myocardial infarction, palpitations, unstable angina, cardiac arrest, dry eye, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, fatty liver disease, cholelithiasis, hearing loss, erectile dysfunction, goiter, anemia, decreased appetite, obesity, drowsiness, hyponatremia, vitamin D deficiency, dermoid cyst, seborrheic dermatitis, atopic dermatitis, nummular eczema, sweat rash, sebaceous gland hyperplasia, lumbar spinal stenosis, myalgia, limb pain, musculoskeletal chest pain, cervical stenosis, fibromyalgia, flank pain, fracture pain, muscle weakness, osteoarthritis, astigmatism, allergic conjunctivitis, blurred vision, corneal erosion, macular fibrosis, conjunctival injection, pathological myopia, retinal detachment, retinal crystals, retinal vein occlusion, traction retinal detachment, eyelid swelling, visual impairment, vitreous floaters, vitreous hemorrhage, epistaxis, age-related dyspnea, wet cough, residual phlegm, skin laceration, rib fracture, long ligament syndrome, atherosclerosis, deep vein thrombosis, diabetic vascular disease, peripheral arterial occlusive disease, unstable angina, hypertension, insomnia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is advisable to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature. This will help safely preserve the medication's effectiveness.

Appearance and packaging

Appearance

Yellow film-coated tablets that are convex on both sides and round in shape

Package unit

Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle, PTP - 30 tablets/PTP [10 tablets/PTP × 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.